Home › Research › Disparities
Treatment of Restless Legs Syndrome Improves Agitation and Sleep in Persons with Dementia: A Randomized Trial
Kathy Culpepper Richards, Liam Fry, Alicia J Lozano, Wenyan Ji, Janet Morrison, Katherine Carroll Britt, Donald L. Bliwise, Nalaka Sudheera Gooneratne et al.. Journal of the American Medical Directors Association, 2025-04-02
Topic: Risk, prevention and care in population studies
Plain-language summary
Mean age ± SD was 83.4 ± 9.1 years. Most were female (72.0%), white (92.3%), non-Hispanic (84.6%), and lived in nursing homes (76.9%). Nighttime agitation, by group over time, was significant at 8 weeks (estimate, -1.67; P = .003) and 2 weeks. Total sleep time (actigraphy) by group over time was significant at 8 weeks (estimate, 48.45; P = .026). Observed nighttime wake by group over time was significant at 2 (estimate, -12.54; P = .006) and 8 weeks (estimate, -11.12; P = .015). The number having ≥1 adverse events was 60 in the GEn group (81.1%) and 50 in the placebo group (68.5%); with 12 serious adverse events in placebo and 10 in the GEn group. The GEn group had a trend toward more falls (P = .066). CONCLUSIONS AND Our findings suggest a novel approach for nighttime agitation in persons with dementia: assessing for RLS and initiating interventions. Larger and longer trials are needed.
What this study adds
Evidence grade: High
This is a trial of 147 participants. This randomized trial found that treating restless legs syndrome improved nighttime agitation and sleep in persons with dementia, though the treatment group had more adverse events and a trend toward more falls. Reported effect size: 72.0%; 92.3%; 84.6%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Richards, K. C., Fry, L., Lozano, A. J., Ji, W., Morrison, J., Britt, K. C., et al. (2025). Treatment of Restless Legs Syndrome Improves Agitation and Sleep in Persons with Dementia: A Randomized Trial. Journal of the American Medical Directors Association. https://doi.org/10.1016/j.jamda.2025.105485
Vancouver
Richards KC, Fry L, Lozano AJ, Ji W, Morrison J, Britt KC, et al. Treatment of Restless Legs Syndrome Improves Agitation and Sleep in Persons with Dementia: A Randomized Trial. Journal of the American Medical Directors Association. 2025. doi:10.1016/j.jamda.2025.105485. PMID: 39909068.
BibTeX
@article{richards2025-39909068,
author = {Richards, Kathy Culpepper and Fry, Liam and Lozano, Alicia J and Ji, Wenyan and Morrison, Janet and Britt, Katherine Carroll and Bliwise, Donald L. and Gooneratne, Nalaka Sudheera and others},
title = {{Treatment of Restless Legs Syndrome Improves Agitation and Sleep in Persons with Dementia: A Randomized Trial}},
journal = {Journal of the American Medical Directors Association},
year = {2025},
doi = {10.1016/j.jamda.2025.105485},
pmid = {39909068},
url = {https://doi.org/10.1016/j.jamda.2025.105485}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Most were female (72.0%), white (92.3%), non-Hispanic (84.6%), and lived in nursing homes (76.9%).
- Nighttime agitation, by group over time, was significant at 8 weeks (estimate, -1.67; P = .003) and 2 weeks.
- Total sleep time (actigraphy) by group over time was significant at 8 weeks (estimate, 48.45; P = .026).
- Observed nighttime wake by group over time was significant at 2 (estimate, -12.54; P = .006) and 8 weeks (estimate, -11.12; P = .015).
- The number having ≥1 adverse events was 60 in the GEn group (81.1%) and 50 in the placebo group (68.5%); with 12 serious adverse events in placebo and 10 in the GEn group.
Why it matters
This randomized trial found that treating restless legs syndrome improved nighttime agitation and sleep in persons with dementia, though the treatment group had more adverse events and a trend toward more falls. It suggests a novel approach for managing nighttime agitation, but larger and longer trials are needed.
New to this subject? Start with our plain-English guide: Disparities →
Study details
- Study designrandomized controlled trial
- Participants147
- Effect size72.0%; 92.3%; 84.6%
- Evidence strengthHigh
How this study scored 65/100
Published in a peer-reviewed journal, and it is a randomized controlled trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of the American Medical Directors Association) |
| Journal's citation record | 2 / 4 | Journal of the American Medical Directors Association: journal h-index 172 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 147 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 2 / 7 | Cited 5 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 3.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Alexandra L. Hanlon: h-index 75 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Pennsylvania: institution h-index 1,859 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39909068) |
| Free to read | 2 / 2 | Free to read |
| Total | 65 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.jamda.2025.105485
- PubMed: 39909068
- Original source →
- Free full text: Journal of the American Medical Directors Association →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Disparities from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.